Fig. 2

Treatment sequencing for patients who received first-line treatment for advanced NSCLC with NSQ A and B or SQ C and D histology in the pre– and post–I-O periods, respectively. Data for categories reflecting treatment of between 1 and 5 patients are masked and have been allocated a standardized line thickness in each of the Sankey diagrams, relative to the respective total number of patients. As such, the thickness of lines may not always correspond as patients transition through the sequence of treatments. Abbreviations: 1L first line; 2L second line; 3L third line; 4L fourth line; I-O immuno-oncology; mAb monoclonal antibody; Non-platinum non-platinum chemotherapy; NSCLC non-small cell lung cancer; NSQ non-squamous; Platinum platinum-based chemotherapy; SQ squamous; TKI tyrosine kinase inhibitor